36052-27-4 Usage
Description
3-Aminopyridine-2-carboxylic acid methyl ester is an organic compound that serves as a versatile intermediate in the synthesis of various organic and pharmaceutical compounds. It is characterized by its amino and ester functional groups, which contribute to its reactivity and potential applications in chemical and pharmaceutical industries.
Uses
Used in Organic Synthesis:
3-Aminopyridine-2-carboxylic acid methyl ester is used as an organic synthesis intermediate for the preparation of a wide range of chemical compounds. Its amino and ester groups make it a valuable building block for the development of new molecules with diverse properties and applications.
Used in Pharmaceutical Industry:
3-Aminopyridine-2-carboxylic acid methyl ester is used as a pharmaceutical intermediate, playing a crucial role in the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of novel pharmaceutical compounds with potential applications in various medical fields.
Used in Laboratory Research and Development:
3-Aminopyridine-2-carboxylic acid methyl ester is utilized in laboratory research and development processes, where it is employed to study its chemical properties, reactivity, and potential applications in the synthesis of new compounds. This research contributes to the advancement of chemical and pharmaceutical sciences.
Used in Chemical Production Processes:
3-Aminopyridine-2-carboxylic acid methyl ester is also used in chemical production processes, where it serves as a key intermediate in the manufacturing of various chemical products. Its versatility and reactivity make it an essential component in the production of a range of chemicals with different applications.
Synthesis
To a solution of 3-aminopyridine-2-carboxylic acid (20 g, 144.9 mmol) in methanol (300 mL) was added conc. sulfuric acid (5.4 mL), and the mixture was heated under reflux for 5 days. The reaction mixture was concentrated under reduced pressure, water was added thereto, and sodium carbonate was added thereto until the complete of foaming. The mixture was extracted with dichloromethane (x3), the organic layer was dried over sodium sulfate, and the solvent was evaporated under reduced pressure to give methyl 3-aminopyridine-2-carboxylate (17.0 g, 77%) as a pale yellow solid. 1H-NMR(300MHz,CDCl3):δ3.95(3H,s),5.72(2H,brs),7.03(1H,dd,J=0.99,8. 35Hz),7.18-7.21(1H,m),8.05(1H,dd,J=0.96,4.04Hz).
Check Digit Verification of cas no
The CAS Registry Mumber 36052-27-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,0,5 and 2 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 36052-27:
(7*3)+(6*6)+(5*0)+(4*5)+(3*2)+(2*2)+(1*7)=94
94 % 10 = 4
So 36052-27-4 is a valid CAS Registry Number.
InChI:InChI=1/C7H8N2O2/c1-11-7(10)6-5(8)3-2-4-9-6/h2-4H,8H2,1H3
36052-27-4Relevant articles and documents
PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS
-
Page/Page column 95, (2021/02/19)
The present invention provides a compound of Formula (I): (I) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).
Dual-Stage Picolinic Acid-Derived Inhibitors of Toxoplasma gondii
Khalifa, Muhammad M.,Martorelli Di Genova, Bruno,McAlpine, Sarah G.,Gallego-Lopez, Gina M.,Stevenson, David M.,Rozema, Soren D.,Monaghan, Neil P.,Morris, James C.,Knoll, Laura J.,Golden, Jennifer E.
supporting information, p. 2382 - 2388 (2020/11/05)
Toxoplasma gondii causes a prevalent human infection for which only the acute stage has an FDA-approved therapy. To find inhibitors of both the acute stage parasites and the persistent cyst stage that causes a chronic infection, we repurposed a compound library containing known inhibitors of parasitic hexokinase, the first step in the glycolysis pathway, along with a larger collection of new structural derivatives. The focused screen of 22 compounds showed a 77% hit rate (>50% multistage inhibition) and revealed a series of aminobenzamide-linked picolinic acids with submicromolar potency against both T. gondii parasite forms. Picolinic acid 23, designed from an antiparasitic benzamidobenzoic acid class with challenging ADME properties, showed 60-fold-enhanced solubility, a moderate LogD7.4, and a 30% improvement in microsomal stability. Furthermore, isotopically labeled glucose tracing revealed that picolinic acid 23 does not function by hexokinase inhibition. Thus, we report a new probe scaffold to interrogate dual-stage inhibition of T. gondii.
HETEROCYCLIC COMPOUND
-
Paragraph 1070, (2016/03/18)
The present invention provides a heterocyclic compound having an RORγt inhibitory action. The present invention relates to a compound represented by the formula (I): wherein Ar is a the partial structure (1) to the partial structure (5), Q is a bivalent group selected from the group consisting of (Ia)-(If), and B is a ring optinally having substituent(s), or a salt thereof.
